Clinical trials are not risk-free, and nobody should tell you they are. What they are is heavily supervised: every trial in Australia is reviewed by an independent ethics committee before it opens, notified to or approved by the TGA, run to international good clinical practice standards, and monitored while it runs. Your safety outranks the data.
The honest version of the answer has two halves. Here's the second half, the part that gets left out of most articles: some of the risk is real, unavoidable, and yours to weigh.
What actually protects you in a clinical trial?
Seven layers, and they're worth knowing by name so you can check each one:
- Independent ethics review. A human research ethics committee (HREC) reviews the protocol, the consent form and the risk-benefit balance before a single participant is enrolled. HRECs include laypeople, not just doctors, and they're independent of the company running the trial. Approval can be withdrawn.
- Regulatory oversight. Trials of unapproved therapeutic goods in Australia run under the TGA's Clinical Trial Notification or Clinical Trial Approval schemes. The regulator knows the trial exists and can intervene.
- Good clinical practice (GCP). The ICH E6 guideline for good clinical practice is the international standard Australian trials follow. Its first principle is that the rights, safety and wellbeing of participants prevail over the interests of science. That's not a slogan. It's the sentence auditors hold sites to.
- Informed consent as a process. Not a signature. You're entitled to time, plain-language explanation, answers, and re-consent if new safety information emerges mid-trial. See your rights as a participant.
- Phased design. Studies escalate deliberately: small doses in few people before larger doses in more people. Each phase has to clear its safety bar before the next one opens.
- Continuous safety monitoring. Adverse events are recorded and graded at every visit. Serious events are reported to the sponsor within tight timeframes, and onward to the ethics committee and the regulator. Many trials also have an independent data safety monitoring board that reviews accumulating data and can halt a study.
- Stopping rules. Protocols specify in advance the events that pause or stop dosing, for you individually or for the whole trial.
None of this makes an experimental treatment predictable. It means somebody is required to notice, act and report when something goes wrong, and there is a paper trail if they don't.
What are the real risks?
- Side effects nobody has seen yet. The earlier the phase, the less is known. A Phase 1 study may have no human safety data at all before it starts.
- The treatment may not work. Most investigational treatments don't make it to registration. Taking part is not a route to a treatment that works. It's a route to finding out.
- You may not receive the active treatment. Placebo or an active comparator is standard in Phase 3 design.
- Extra procedures. More blood draws, more scans, sometimes biopsies or lumbar punctures you wouldn't have had in routine care. Each carries its own small risk.
- Time and travel. The most under-estimated cost, and the most common reason people drop out.
- Opportunity cost. Time on a study treatment is time not spent on another option. This is the conversation to have with your treating specialist, not with a recruitment team.
Who is watching a trial while it's running?
| Who | What they're responsible for |
|---|---|
| Principal investigator | Your medical care and safety at the site; clinical decisions |
| Study coordinator | Day-to-day contact, symptom review, escalation |
| Sponsor / CRO monitors | Checking data accuracy and protocol compliance at the site |
| Human research ethics committee | Ongoing ethical oversight; receives safety reports; can suspend approval |
| Data safety monitoring board | Independent review of accumulating safety data across all sites |
| TGA | Regulatory oversight of the trial and the unapproved product |
Are Phase 1 trials more dangerous than Phase 3?
The risk profile is different rather than uniformly worse. Phase 1 studies carry more unknown, because less human data exists. They're also run with the tightest controls in clinical research: purpose-built units, staged dose escalation, one participant dosed ahead of the group in first-in-human studies, continuous monitoring, and immediate access to resuscitation facilities.
Phase 3 trials involve treatments with a known side-effect profile, given to far more people, in ordinary hospital and clinic settings, over much longer periods. The unknowns are smaller but the exposure is longer.
If you want the short version: Phase 1 is intensively supervised uncertainty. Phase 3 is lightly supervised familiarity. Neither is zero.
What happens if something goes wrong?
Tell the site immediately, using the 24-hour contact number you're given at consent. Then:
- You're assessed and treated. Your care comes first, and the study treatment can be paused or stopped for you alone
- The event is documented as an adverse event, graded, and assessed for whether it's related to the study treatment
- Serious adverse events are reported to the sponsor and, where required, to the ethics committee and the TGA
- Suspected unexpected serious reactions can trigger changes to the protocol, the consent form, or the trial's continuation
- Compensation arrangements are described in the consent form. Australian commercial trials typically operate under sponsor indemnity arrangements covering injury caused by the study treatment. Read that section, and ask what it covers and what it excludes. It's one of the two or three sections in a PICF worth reading twice.
How do I check a trial is legitimate?
Do these five checks before your screening visit:
- Find it on a registry. ANZCTR or ClinicalTrials.gov. A registration number should be on the consent form
- Check the ethics approval. The consent form should name the HREC that approved the study and give an approval reference
- Identify the site and the investigator. A named doctor at a real clinical facility, contactable independently
- Read the consent form before your visit. Ask for it in advance. Any site that won't send it early is a site to walk away from
- Watch for the disqualifiers: you're asked to pay to participate, there's no written consent form, you're pressured to sign on the spot, you're promised a cure or told there's no risk, or contact details are a mobile number and nothing else
Any one of those five red flags is enough. You don't need a second.
So should you do it?
If you're a patient with a serious condition and your specialist thinks a trial is a reasonable option, the supervision in a well-run trial is often more intensive than routine care: more frequent reviews, more testing, faster escalation when something changes. That's a genuine argument in favour, and it's why many participants report feeling closely looked after.
What should stop you is a trial whose demands don't fit your life, a consent conversation that felt rushed, or a site that treated your questions as an obstacle. Those are the signals to trust.
The thing to watch for once you're enrolled: the temptation to downplay a new symptom because you don't want to be dropped from the study. Report it anyway. A trial where participants edit what they report is unsafe for you and useless for everyone who comes after you.
